行情

HALO

HALO

奥洛兹美医疗
NASDAQ

实时行情|Nasdaq Last Sale

19.97
-0.16
-0.79%
盘后: 20.42 +0.45 +2.25% 17:27 01/17 EST
开盘
20.24
昨收
20.13
最高
20.32
最低
19.80
成交量
167.99万
成交额
--
52周最高
20.50
52周最低
14.61
市值
29.25亿
市盈率(TTM)
-72.8035
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

EPS

HALO 新闻

  • The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
  • Benzinga.2天前
  • The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
  • Benzinga.3天前
  • The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance
  • Benzinga.4天前
  • Halozyme Adds $150M to Buyback
  • Benzinga.5天前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

HALO 简况

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
展开

Webull提供Halozyme Therapeutics, Inc.的股票价格，实时市场报价，专业分析师评级，深度图表和免费的股票新闻，以帮助您做出投资决策。